Serum Lipoprotein-a as a Marker of Severity of Coronary Artery Disease in Aortic Valve Sclerosis Patients

CompletedOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

October 1, 2024

Primary Completion Date

May 1, 2025

Study Completion Date

May 1, 2025

Conditions
SerumLipoprotein(A)SeverityCoronary Artery DiseaseAortic Valve Sclerosis
Interventions
OTHER

Serum Lipoprotein-a level

A venous blood sample was taken from each patient a month or so after discharge to check their Lp (a) levels. The samples were centrifuged for 10 minutes at 2-8 °C, after which the serum was divided into aliquots and stored at -20 ° C.

Trial Locations (1)

82511

Sohag University, Sohag

All Listed Sponsors
lead

Sohag University

OTHER

NCT07209631 - Serum Lipoprotein-a as a Marker of Severity of Coronary Artery Disease in Aortic Valve Sclerosis Patients | Biotech Hunter | Biotech Hunter